Gut bacteria and immunotherapy for early-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether the bacteria in your gut (microbiome) can affect how well immunotherapy works for lung cancer that can be surgically removed. You may receive immunotherapy or chemotherapy before surgery to shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 75 years old
- Newly diagnosed with non-small cell lung cancer (stage IIA to IIIB) that is negative for driver genes (like EGFR or ALK)
- No prior cancer treatment like chemotherapy or radiation
- Able to have surgery to remove the tumor after evaluation by your care team
- Good overall health (ECOG score 0 or 1) and adequate lung function for surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests using immunotherapy before surgery or radiation for non-small cell lung cancer. It looks at how safe and effective this approach is and how it affects survival.
This study looks at how your gut bacteria might affect a treatment for lung cancer that combines chemotherapy and immunotherapy before surgery. It aims to see if certain bacteria can help the treatment work better.
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
This trial studies a comprehensive treatment approach for lung cancer that combines immunotherapy given before surgery with standard surgery. It aims to understand how well this approach works by analyzing your medical data and samples.
This study looks at how the bacteria in your gut (microbiome) might affect how well your lung cancer treatment works and what side effects you experience. The goal is to learn if certain gut bacteria can predict treatment response or side effects for people with advanced non-small cell lung cancer.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.